The company
Mesa Laboratories, Inc.
MLAB · Nasdaq
MLAB stood above a rising 150-day average in 33 of the last 52 weekly readings, including each of the last 32 weeks. It is 16.4% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 32 in a row
- Industry in uptrend
- 52% +1 in 4 wk
- Insider buys, 12 months
- $2.7M
- Insider sales, 12 months
- $3.1M
- Officials’ trades on record
- 0
- Institutions holding
- 151 (+0)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.
Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| R. Tony TripenyDirector | bought | 900at $113.69 | 13 Aug 2026filed 17 Aug 2026 |
| Siddhartha KadiaPresident and CEO | bought | 7,093at $112.80 | 13 Aug 2026filed 17 Aug 2026 |
| John James SullivanDirector | sold | 7,093at $112.80 | 13 Aug 2026filed 17 Aug 2026 |
| John SakysCFO | sold | 2,827at $89.50 | 22 Jun 2026filed 23 Jun 2026 |
| Brian David ArchboldSVP Operations | sold | 2,516at $89.50 | 22 Jun 2026filed 23 Jun 2026 |
| Lyndsey Elizabeth CrennenCAO | sold | 442at $89.50 | 22 Jun 2026filed 23 Jun 2026 |
| John SakysCFO | sold | 1,223at $101.27 | 16 Jun 2026filed 17 Jun 2026 |
| Lyndsey Elizabeth CrennenCAO | sold | 118at $101.27 | 16 Jun 2026filed 17 Jun 2026 |
| Brian David ArchboldSVP Operations | sold | 1,151at $101.27 | 16 Jun 2026filed 17 Jun 2026 |
| R. Tony TripenyDirector | bought | 1,315at $76.00 | 10 Mar 2026filed 10 Mar 2026 |
| Mark Christopher CaponeDirector | bought | 1,301at $76.35 | 10 Mar 2026filed 10 Mar 2026 |
| Shiraz Shabanali LadiwalaDirector | bought | 3,500at $72.23 | 10 Mar 2026filed 10 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Long Path Partners LPadded · filed 31 Jul 2026 | 477,126$47.5M | +71,543+17.6% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 440,552$43.9M | +46,701+11.9% |
| Boston Partnersreduced · filed 4 Aug 2026 | 265,149$26.4M | -3,562−1.3% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 237,457$23.6M | +4,814+2.1% |
| AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026 | 203,739$20.3M | +33,177+19.5% |
| Ranger Investment Management, L.P.reduced · filed 13 Aug 2026 | 173,988$17.3M | -28,915−14.3% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 156,979$15.6M | -5,137−3.2% |
| Diamond Hill Capital Management, LLC (Investment Advisor)added · filed 6 Aug 2026 | 155,771$15.5M | +469+0.3% |
| RAYMOND JAMES FINANCIAL INCadded · filed 14 Aug 2026 | 149,937$14.9M | +27,026+22.0% |
| DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026 | 148,395$14.8M | +23,765+19.1% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.